- Home
- EPRX
as 04-22-2025 4:00pm EST
Stocks
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
| Founded: | 2011 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 111.1M | IPO Year: | N/A |
| Target Price: | $9.00 | AVG Volume (30 days): | 8.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.20 - $4.48 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest EUPRAXIA PHARMACEUTICALS INC News
EPRX Breaking Stock News: Dive into EPRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks
Simply Wall St.
a month ago
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
PR Newswire
a month ago
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
CNW Group
2 months ago
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
TipRanks
2 months ago
Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential
CNW Group
2 months ago
Eupraxia Pharmaceuticals Announces CFO Succession
CNW Group
5 months ago
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
CNW Group
5 months ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Compare EPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EPRX EUPRAXIA PHARMACEUTICALS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.